Product Description: Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Binder C, et, al. Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro. Front Immunol. 2020 Nov 11;11:592553.
CAS Number: 288392-69-8
Molecular Weight: N/A
Compound Purity: 99.83
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: CD2